Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) is a multinational, randomized, controlled trial designed to compare the effects of prandial versus fasting glycemic control on risk for cardiovascular outcomes in patients with type 2 diabetes after acute myocardial infarction (AMI). RESEARCH DESIGN AND METHODS—Patients (type 2 diabetes, aged 30–75 years) were randomly assigned within 21 days after AMI to the 1) prandial strategy (PRANDIAL) (three premeal doses of insulin lispro targeting 2-h postprandial blood glucose <7.5 mmol/l) or the 2) basal strategy (BASAL) (NPH twice daily or insulin glargine once daily targeting fasting/premeal blood glucose <6.7 mmol/l). RESULTS—A total of 1,115 patients were randomly assigned (PRANDIAL n = 557; BASAL n = 558), and the mean patient participation after randomization was 963 days (range 1–1,687 days). The trial was stopped for lack of efficacy. Risks of first combined adjudicated primary cardiovascular events in the PRANDIAL (n = 174, 31.2%) and BASAL (n = 181, 32.4%) groups were similar (hazard ratio 0.98 [95% CI 0.8–1.21]). Mean A1C did not differ between the PRANDIAL and BASAL groups (7.7 ± 0.1 vs. 7.8 ± 0.1%; P = 0.4) during the study. The PRANDIAL group showed a lower daily mean postprandial blood glucose (7.8 vs. 8.6 mmol/l; P < 0.01) and 2-h postprandial blood glucose excursion (0.1 vs. 1.3 mmol/l; P < 0.001) versus the BASAL group. The BASAL group showed lower mean fasting blood glucose (7.0 vs. 8.1 mmol/l; P < 0.001) and similar daily fasting/premeal blood glucose (7.7 vs. 7.3 mmol/l; P = 0.233) versus the PRANDIAL group. CONCLUSIONS—Treating diabetic survivors of AMI with prandial versus basal strategies achieved differences in fasting blood glucose, less-than-expected differences in postprandial blood glucose, similar levels of A1C, and no difference in risk for future cardiovascular event rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated postchallenge (2-h oral glucose tolerance test) glucose values have been associated with increased cardiovascular risk independent of fasting plasma glucose in some epidemiologic studies, whereas intervention trials have not shown postprandial glucose to be a cardiovascular risk factor independent of A1C.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [73]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most of the large outcome trials conducted so far have been mostly based on preprandial glucose and A1C targets, with limited evidence of a long-term benefit of targeting PPG alone (49,50).”
From Targets for Glycemic Control (2018) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, manipulating prandial glucose levels failed to impact clinical outcome, and therefore, this remains an unresolved area.142,143”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [143]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, a randomized controlled trial in patients with known CVD found no CVD benefit of insulin treatment plans targeting postprandial glucose compared with those targeting preprandial glucose (73).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [73]
The cited source says what the claim attributes to it.
In the citing paper
“Elevated postchallenge (2-h oral glucose tolerance test) glucose values have been associated with increased cardiovascular risk independent of fasting plasma glucose in some epidemiologic studies, whereas intervention trials have not shown postprandial glucose to be a cardiovascular risk factor independent of A1C.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [73]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 2×
“The Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD) trial (21) demonstrated increased mortality with intensive glycemic goals (A1C of 6.4%), the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial (22) showed similar cardiovascular outcomes wi…”
InfluentialDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 1×
“A similar separation in glycemic control was noted in the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study (18), in which the primary composite cardiovascular end point failed to reach significance between therapies, but the secondary composite end point did reach significance.”
ResultStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,724
Cited by
Items 301–350 of 350
Measurement and Treatment Goal of Postprandial Hyperglycemia
Kim, S. (2012) · Journal of Korean Diabetes · doi:10.4093/jkd.2012.13.1.27 · Cited by 1
Cacciapuoti, F. (2010) · Mediterranean Journal of Nutrition and Metabolism · doi:10.1007/s12349-010-0038-3
Arola, O. T., Nevalainen, P. I., Kotila, M., Huhtala, H., & Alanko, J. (2014) · The Open Diabetes Journal · doi:10.2174/1876524601407010020 · Cited by 1
“By contrast, the HEART2D Study [17] found no difference in future cardiovascular event rates after myocardial infarction between prandial strategy groups and basal strategy groups in diabetic patients, while the difference of PPG between the groups was negligible.”
ResultTaketa, K., Matsumura, T., Furukawa, N., & Araki, E. (2012) · Clinical Medicine Reviews in Vascular Health · doi:10.4137/cmrvh.s7434
Marijana, B.-P. (2013) · Medicinski casopis · doi:10.5937/mckg47-3470
[Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
Reboldi, G. (2009) · PubMed
Providing cardiovascular benefits with safe diabetes therapy
Ilany, J. (2009) · Therapy · doi:10.2217/thy.09.29
Variabilité glycémique et hyperglycémie postprandiale : quelle importance au-delà del’HbA1c?
Monnier, L., Colette, C., Wojtusciszyn, A., & Dejager, S. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30260-1
García, D., & Francisca, A. (2014) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Corriger la glycémie postprandiale des patients diabétiques : une exigence moderne !
Slama, G. (2009) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(09)74749-2
Ammon, H. P. T., Burchard, A., Drexel, H., Füchtenbusch, M., Hauner, H., Matthaei, S., Merkel, M., Müller‐Wieland, D., Pfohl, M., Roden, M., et al. (2014)
Wie kann dieser Notfall verhindert werden?
Holstein, A., Duning, T., Kleophas, W., Schneider, C. A., & Rüßmann, H.-J. (2012) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-012-0524-2
Effectiveness of Individual-Level Interventions to Prevent Vascular Complications
Adler, A. (2010) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195317060.003.0017
Cardiopathie ischémique et infarctus chez le diabétique
Payot, L., & Feuvre, C. L. (2015) · Time to knit · doi:10.1016/s1166-4568(15)47041-x · Cited by 1
Krasilnikova, E. I., Pavlov, P., & Elena, K. (2009) · CyberLeninK (CyberLeninka)
Prise en charge du diabétique après infarctus du myocarde
Halbron, M., Jacqueminet, S., & Grimaldi, A. (2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00021-4
Effects of Postmeal Walking on Postprandial Glucose Control and Oxidative Stress
Knurick, J. R. (2015)
Glycaemic variability and Mortality in critically ill patients
Khot, R. S. (2017) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v5i7.239
The Effect of Cardiovascular Risk Factors on the Coronary Circulation
Valenzuela-García, L. F., Matsuzawa, Y., & Lerman, A. (2017) · Springer eBooks · doi:10.1007/978-1-4471-5245-3_6
Therapie postprandialer Blutzuckerspitzen – sinnvoll oder nur Blutzuckerkosmetik?
Müller, U. A. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0260-4
“Beide Gruppen erreichten eine vergleichbare Verbesserung des HbA1c-Werts sowie eine vergleichbare Verminderung des kardiovaskulären Risikos unabhängig von den erreichten postprandialen Plasmaglukosewerten [17].”
BackgroundInicjacja i intensyfikacja leczenia insulinami ludzkimi w cukrzycy typu 2 — podejście praktyczne
Sieradzki, J. (2012) · Via Medica Journals
Fisher, M. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch39
Glycemic Targets and Prevention of Chronic Complications
Cernea, S., Cahn, A., & Raz, I. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_14-1
Self-citationDésordres glycémiques et complications diabétiques : physiopathologie
Monnier, L., & Colette, C. (2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00009-3
Kreß, S. (2019) · Diabetes aktuell · doi:10.1055/a-0836-1591
Al-hilly, A. S. A.-D. A. R. (2018) · AL-QADISIYAH MEDICAL JOURNAL · doi:10.28922/qmj.2018.14.25.27-34
Intermittent high glucose promotes expression of proinflammatory cytokines in monocytes
Li-boQi, Y., & Ag, S. B. (2011)
Rábai, M., & Habon, T. (2017) · Diabetologia Hungarica · doi:10.24121/dh.2017.33
Stümvoll, M., & Tönjes, A. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0684-1 · Cited by 1
Thérapeutique des désordres glycémiques
Monnier, L., & Colette, C. (2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00007-x
Thérapeutique des désordres glycémiques
(2010) · Elsevier eBooks · doi:10.1016/b978-2-294-70868-8.50007-4
(2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00004-4
Ruquiyyah, K., & Hoda, Q. (2020) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2020.7.1.0242
“There are GLP-1 receptors on the heart and questions were raised in view of the DPP-4 inhibitor results on heart failure [54], [55].”
BackgroundSánchez, F. B. R., Sanz‐Cánovas, J., Carmona, J. M., & Jansen‐Chaparro, S. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.019 · Cited by 1
Praktische Umsetzung einer Insulintherapie bei Typ-2-Diabetes: Einfache und komplizierte Fälle
Liebl, A. (2021) · Diabetes aktuell · doi:10.1055/a-1576-9316
“Auch eine Therapie mit kurzwirksamen Insulinen beeinflusst das kardiovaskuläre Ergebnis nicht [12].”
BackgroundDiabetestherapie bei fortgeschrittenen Lebererkrankungen und Leberzirrhose
Bojunga, J., & Friedrich‐Rust, M. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00822-z
“Vorteil hinsichtlich kardiovaskulärer Endpunkte nachweisbar [40].”
Ogiso, K., Shayo, S. C., Kawade, S., Hashiguchi, H., Deguchi, T., & Nishio, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-731463/v1
Ammon, H. P. T., Burchard, A., Drexel, H., Füchtenbusch, M., Häring, H., Hauner, H., Joost, H., Matthaei, S., Merkel, M., Müller‐Wieland, D., et al. (2014) · Springer eBooks · doi:10.1007/978-3-642-41358-2_4
Current literature in diabetes
(2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1034 · Cited by 1
Glycemic Targets and Prevention of Chronic Complications
Cernea, S., Cahn, A., & Raz, I. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_14
Self-citationThérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Type 2 diabetes: glycaemic control
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch10
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00004-x · Cited by 1
Prise en charge du diabétique après infarctus du myocarde
Halbron, M., Jacqueminet, S., & Grimaldi, A. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00024-5
Désordres glycémiques et complications diabétiques : physiopathologie
Monnier, L., & Colette, C. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00009-9 · Cited by 1
ESTRÊLA, D. D. S. G., RIBAS, J. L. L., & Carneiro, D. O. (2022) · Visão Acadêmica · doi:10.5380/acd.v23i3.84847
Kröger, J. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00941-1
Alotaiby, N. L. M., Alotaiby, A. A. S., Al-Falih, T. A., Alqahtani, S. M., Fadan, O. Y., & Khader, A. K. H. (2017) · International Journal of Health Sciences · doi:10.53730/ijhs.v1ns1.15342
Xing, Y., Wu, M., Liu, H., Li, P., Pang, G., Zhao, H., & Wen, T. (2024) · Figshare · doi:10.6084/m9.figshare.25329765
Nyane, N., Balmith, M., Ravhengani, M., & Flepisi, B. (2025) · SA pharmaceutical journal. · doi:10.36303/sapj.3196
Metadata
- Authors
- Raz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., & Jacober, S. J.
- Affiliations
- Hadassah Medical Center (IL)
- Emory University (US)
- Medical University of Silesia (PL)
- Medical University of Białystok (PL)
- Endocrinology, Diabetes and Metabolic Diseases, University Hospital Dubrava, Zagreb, Croatia
- Cardiology, Herzzentrum Ludwigshafen, Ludwigshafen, Germany
- Medical Department, Bajcsy-Zsilinszky Teaching Hospital, Budapest, Hungary
- Eli Lilly (United States) (US)
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-03-01
- Volume
- 32
- Issue
- 3
- Pages
- 381-386
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2646013
- OpenAlex
- W2172111876
- Cited by
- 351
- References
- 26
- Citations by year
- 2025: 5 · 2024: 9 · 2023: 2 · 2022: 5 · 2021: 12 · 2020: 13 · 2019: 18 · 2018: 20 · 2017: 22 · 2016: 28 · 2015: 36 · 2014: 25 · 2013: 35 · 2012: 24
- FWCI
- 29.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- type 2 diabetes, acute myocardial infarction, insulin lispro, basal insulin, postprandial blood glucose, glycemic excursions, cardiovascular outcomes, HbA1c, lack of efficacy
- MeSH terms
- Insulin Glargine, Adult, Aged, Body Weight, Cardiovascular System, Diabetes Mellitus, Type 2, Drug Administration Schedule, Fasting, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Risk Factors, Treatment Outcome, Postprandial Period, Insulin, Long-Acting, Insulin Lispro
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.